Literature DB >> 28373006

Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types.

Athanasios Kotsakis1, Vassilis Georgoulias2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28373006     DOI： 10.1016/S1470-2045(17)30227-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience.

Authors:  Qingqing Xie; Caixia Sun; Zhenghua Fei; Xujing Yang
Journal:  Patient Prefer Adherence       Date:  2022-01-04       Impact factor: 2.711

Review 2.  Cancer Immunotherapies: Are They as Effective in the Elderly?

Authors:  Kate Poropatich; Joel Fontanarosa; Sandeep Samant; Jeffrey A Sosman; Bin Zhang
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 4.271

Review 3.  Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

Authors:  Ruifang Sun; Jinfen Wang; Ken H Young
Journal:  Crit Rev Oncog       Date:  2017

4.  Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

Authors:  Italia Grenga; Renee N Donahue; Morgan L Gargulak; Lauren M Lepone; Mario Roselli; Marijo Bilusic; Jeffrey Schlom
Journal:  Urol Oncol       Date:  2017-11-02       Impact factor: 3.498

5.  Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma.

Authors:  Musaffe Tuna; Wenbin Liu; Christopher I Amos; Gordon B Mills
Journal:  Neoplasia       Date:  2019-11-14       Impact factor: 5.715

Review 6.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

Review 7.  Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.

Authors:  Rui-Fang Sun; Qian-Qian Yu; Ken H Young
Journal:  Chronic Dis Transl Med       Date:  2018-03-12

8.  The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer.

Authors:  Dongfang Tang; Dandan Zhao; Yun Wu; Ruyong Yao; Lin Zhou; Liming Lu; Wen Gao; Yifeng Sun
Journal:  J Cell Mol Med       Date:  2018-05-04       Impact factor: 5.295
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.